xyfcvdessuuwtfzveqrt

Strategy

Jun 20, 2017
Most challenges boil down to two simple categories: "complicated" and "complex". Knowing how to categorize each problem is key to solving it, writes Steve Figman.
Jun 12, 2017
Pharmaceutical Executive
With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.
Jun 11, 2017
Jackie DeAngelis outlines three common mistakes that hinder access attainment when launching a new drug.
May 12, 2017
Pharmaceutical Executive
For pharma, diagnosing what ails or strengthens performance in this critical corporate discipline may help reshape business prognosis.
May 09, 2017
Peter Young offers a summary of the strategic issues facing the biopharma industry, reviews recent stock market, M&A and financing activity, and looks at the implications for senior management.
Apr 26, 2017
By Pharmaceutical Executive Editors
A new report from QuintilesIMS asks, it more advantageous to take a product to market by "Going It Alone" or by partnering with an established pharma company?
Mar 09, 2017
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Facing mixed market signals, biotech companies look to rise above the fray in advancing new-wave discoveries to the clinical finish line.
Feb 28, 2017
Pharmaceutical Executive
A panel of biopharma executives responsible for the Latin America business discuss investment, market access, and reimbursement issues in this key regional growth market for the life sciences industry.
Feb 21, 2017
Neil Grubert discusses the key trends in market access this year and beyond.
Feb 10, 2017
Haydn Evans looks at the role of intellectual property (IP) management in protecting pharmaceutical company products.
lorem ipsum